Overview

• Novo Nordisk terminated its April collaboration with Hims & Hers after accusing the telehealth company of selling unapproved, mass-compounded versions of Wegovy that breach FDA compounding laws
• The FDA removed Wegovy’s semaglutide shortage designation in February and set a May 22 deadline to cease compounded versions, but Hims & Hers announced plans to keep offering “personalized” doses
• Phase 3 trials showed CagriSema patients lost an average of 22.7% of body weight in obesity studies and 15.7% in diabetes studies over 68 weeks, falling short of the 25% target and leading Novo Nordisk to plan regulatory filings early next year
• Novo Nordisk’s U.S.-listed shares fell more than 5% and Hims & Hers stock plunged nearly 30% following news of the split and the release of CagriSema trial results
• Novo Nordisk launched Wegovy in India in five dosage strengths priced between ₹17,345 and ₹26,050 per month as it positions itself ahead of semaglutide patent expiry in 2026